Shares of Bionano Genomics (NASDAQ: BNGO) are soaring 9.92% in pre-market trading on Friday, continuing the upward momentum following Thursday's impressive 25.13% intraday gain. The surge comes on the heels of the company's outstanding first-quarter 2025 earnings report, which significantly exceeded analyst expectations and painted a brighter picture for the genomics firm's future.

Bionano Genomics reported a narrower-than-anticipated loss of $1.15 per share for Q1 2025, substantially outperforming the analyst consensus estimate of a $3.02 loss. This marks a remarkable improvement from the $35.75 per share loss reported in the same period last year. Although revenue decreased 25.88% year-over-year to $6.50 million, it still managed to surpass analyst estimates of $6.23 million. The company highlighted an impressive gross margin of 46% for the quarter, indicating enhanced operational efficiency.

Looking ahead, Bionano Genomics provided an optimistic full-year 2025 revenue outlook, projecting between $26 million to $30 million. The company also reaffirmed its plan to install 15 to 20 new Optical Genome Mapping (OGM) systems in 2025, signaling continued focus on expanding its technology's adoption. Furthermore, Bionano reported an extended cash runway into the first quarter of 2026, supported by cost-saving measures, capital efficiency, debt restructuring, and recent equity capital raises. This improved financial position, combined with the strong quarterly performance and positive outlook, has bolstered investor confidence in the company's growth prospects, contributing to the significant stock price surge in both after-hours trading on Wednesday and during Thursday's session, with the momentum carrying into Friday's pre-market trading.